KalVista Pharmaceuticals is developing novel plasma kallikrein inhibitors, which represent a new approach to the treatment of DME, the leading cause of adult visual loss in developed countries.

Latest News
KalVista Pharmaceuticals Brings Expertise to New European Consortium Focused on the Discovery and Development of Novel Eye Therapeutics
KalVista Pharmaceuticals Wins £2.4m Biomedical Catalyst Grant to Further Develop Oral Plasma Kallikrein Inhibitors as a Treatment for Diabetic Macular Edema
Registered Office: Phi House, Enterprise Road, Southampton Science Park, Southampton, SO16 7NS. Registered in England. Registered No: 07543947